Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
about
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationThe immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunityAntibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantPrevention of maternal cytomegalovirus infection: current status and future prospects.Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus.Cytomegalovirus vaccines: at last, a major step forwardCombination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunityInfected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particlesUpdate on the current status of cytomegalovirus vaccines.Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.Cytomegalovirus vaccines.Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Alphavirus replicon vaccines.RNA-based viral vectors.Cytomegalovirus vaccines under clinical developmentProgress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
P2860
Q24634730-4ADF774B-729F-4837-BDDC-B042A192911AQ27692570-2C0101D3-71B0-4B85-8D5E-37C28A326B9AQ28749317-2AB09634-C9D5-4627-939F-D6ED65C2F219Q33877513-50E30AE8-B6F0-4364-93B4-F8EBE6A27259Q34272089-906BEE75-37EC-42AB-A658-FCB9489357BEQ34349745-724D731D-9B92-4BA6-A3C6-35194525CB37Q35114611-61EED335-DE3D-4C87-A3BD-2A2AF6FBA11DQ35270894-9009BA3E-272B-41D1-B76B-3980C5683F3BQ35527105-26E33346-0F7D-4427-B07B-37DC0F04212FQ36086236-2390B70C-355F-4132-B0C3-7D744D6A5C8AQ36458651-A9C6FFC4-F9D5-426D-A7A7-C76C8A4A7408Q36678423-AA0E1F6B-2520-4B93-A98D-516BAADAB7A4Q36759944-E2FC6EA0-0C1D-4400-8365-4AC0F1630C17Q37252609-0274B0DF-56AB-45E4-B7D3-E79CFCDDEEB7Q37332494-BF6020BD-BF4B-4CEB-978E-A35E3A1EEBE6Q37409233-73EF9038-F56E-456F-AA50-31A36CA3AD7BQ37559627-7448E10E-9DEC-444D-B0C8-A2DECB706399Q37995803-8C07AFA0-66F6-4AA2-BCB8-CBFD1B3547BEQ38266413-2907685F-A08F-4512-9DF6-47FE8A6DC790Q42380888-C0DBA466-DF08-4CC2-9388-81A6C17CB4B6Q47115255-C3A06F73-D9F8-46CE-AD68-E1F4AE8F9D29Q47605886-92FEFE98-9BD3-4DD5-86F0-333F4FFBBBB6
P2860
Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 August 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@en
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@nl
type
label
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@en
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@nl
prefLabel
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@en
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@nl
P2093
P2860
P1433
P1476
Development and preclinical ev ...... e vaccine for cytomegalovirus.
@en
P2093
Andrew Graham
Bruce Burnett
Elizabeth A Reap
Jeffrey D Chulay
John Morris
Maureen Maughan
Robert A Olmsted
Robert E Esch
Sarah Negri
Sergey A Dryga
P2860
P304
P356
10.1016/J.VACCINE.2007.08.016
P407
P577
2007-08-30T00:00:00Z